Evidence · Oncolytic virotherapy
The evidence behind H101,
checked against the sources.
Twenty years of H101 research, from a 2004 Phase III trial to 2025 surgical consensus. Every figure here was checked against the published abstract or full text. Each study's design is shown so you can see what is established and what is still exploratory.
Quick answer
How strong is the evidence for oncolytic virus therapy with H101?
It is strongest in head and neck cancer. A Phase III randomised trial reported a 78.8% response rate with H101 + cisplatin/5-FU vs 39.6% with chemotherapy alone, and H101 was approved for nasopharyngeal carcinoma in 2005. In liver cancer, retrospective cohorts of 175 to 476 patients from Sun Yat-sen University Cancer Center showed better response and survival when H101 was added to TACE. The 2022 CSCO consensus recommends this as an initial-treatment option. PD-1 combinations rest on a pilot study (n=18) and conference abstracts, and remain unproven.
Phase III
Head & neck / oesophageal SCC
78.8% vs 39.6% response with chemo
Xia et al., Ai Zheng 2004
476
Largest HCC cohort
Propensity-matched, TACE + H101 vs TACE
He et al., Chin J Cancer 2017
Recommended
CSCO 2022
H101 + TACE as initial HCC option
CSCO consensus 2022
IIb / C
Perioperative grade
Intra-operative perfusion, exploratory
2025 HCC consensus
3
ASCO 2024 abstracts
Gastric liver mets, gynaecological, cholangiocarcinoma
J Clin Oncol 2024 suppl
2004–2025
Years of clinical data
From Phase III to perioperative consensus
See references
Guidelines
Three Chinese consensus documents.
CSCO 2022 consensus
Chinese expert consensus on recombinant oncolytic adenovirus (CSCO Immunotherapy Committee and Shanghai Anti-Cancer Association). For unresectable HCC with Child-Pugh A/B and no extrahepatic spread, hepatic-artery H101 + TACE may be considered as initial treatment.
Supporting studies graded 3c
2023 intra-arterial HCC consensus
Chinese Medical Doctor Association interventional drug group (Chin J Intern Med 2023;62(7)). Discusses oncolytic viruses under new approaches to intra-arterial combination therapy.
Exploratory direction
2025 perioperative HCC consensus
Chin J Dig Surg 2025;24(6). Recommendation 19: intra-operative immunotherapy is still exploratory, and local oncolytic-virus perfusion may help control local recurrence.
Evidence IIb · grade C
Key studies
H101 studies at a glance
Retrospective and single-arm designs cannot rule out selection bias, so treat their effect sizes as estimates rather than guarantees.
| Study | Design | Setting | Main finding |
|---|---|---|---|
| Xia et al., Ai Zheng 2004 | Phase III randomised (160 enrolled, 123 analysed) | Head & neck / oesophageal SCC | Response 78.8% (H101 + PF) vs 39.6% (PF) |
| Dong et al., Med Oncol 2014 | Retrospective, 149 vs 150 | Unresectable HCC, TACE ± H101 | PFS 240 vs 196 days; OS 1,526 vs 1,236 days |
| Lin et al., BMC Cancer 2015 | Retrospective, 87 vs 88 | Unresectable HCC, TACE ± H101 | CR 28.7% vs 14.8%; median OS 12.8 vs 11.6 mo |
| He et al., Chin J Cancer 2017 | Retrospective, matched 238 vs 238 | Intermediate–advanced HCC | 3-yr OS 40.5% vs 22.4% |
| Wu et al., J Gastrointest Oncol 2021 | Retrospective | HCC after resection, TACE ± H101 | Lower recurrence and metastasis (P < 0.05); liver function similar |
| Zhang et al., Mol Ther Oncolytics 2022 | Retrospective, 40 patients | Malignant ascites, intraperitoneal | Ascites response 40%, control 75%; CD8+ T cells and DCs increased |
| Yi et al., ESMO Open 2024 | Single-arm pilot, n=18 | Refractory advanced HCC + nivolumab | ORR 11.1%, DCR 38.9%, median OS 15.04 mo; no grade 3–4 events |
ASCO 2024
Three Chinese studies at ASCO 2024
Three Chinese oncolytic-virus abstracts appeared at the 2024 ASCO Annual Meeting. Conference abstracts are preliminary and have not been peer-reviewed as full papers.
| Abstract | Study | First-author centre |
|---|---|---|
| 2635 | TROJAN 021: H101 + immune checkpoint inhibitors in liver-metastatic gastric cancer, prospective multicentre Phase II | Shanghai Tenth People's Hospital |
| 5536 | Intratumoral H101 in persistent / recurrent / metastatic gynaecological cancer, with tumour-microenvironment analysis | First Affiliated Hospital of Xi'an Jiaotong University |
| e16265 | Oncolytic virus combined with HAIC of mFOLFOX for intrahepatic mass-forming cholangiocarcinoma, single-centre single-arm prospective | Beijing Tsinghua Changgung Hospital |
Limitations
What the evidence doesn't yet show
No randomised trial has confirmed a survival benefit for H101 + TACE in liver cancer; the supporting cohorts are retrospective and come largely from one centre. PD-1 combination data come from a single 18-patient pilot and conference abstracts. Uses beyond nasopharyngeal carcinoma are off-label in China, and H101 is not approved outside China.
FAQ
Oncolytic virus evidence — answered.
- Are there clinical trials of oncolytic virus therapy?
- Yes. In China, recent H101 studies include TROJAN 021 (Phase II, liver-metastatic gastric cancer) and studies in gynaecological cancer. Other oncolytic viruses, such as OH2, are in clinical trials but do not yet have marketing approval. Whether international patients are eligible varies by trial.
- What is the success rate of oncolytic virus therapy?
- It depends on the cancer and the combination. In the Phase III trial, 78.8% responded to H101 + cisplatin/5-FU vs 39.6% to chemotherapy alone. With TACE in liver cancer, 28.7% had a complete response and 60.9% a complete or partial response. In the PD-1 pilot for refractory liver cancer, 11.1% responded. These figures come from selected study populations and don't predict any individual's outcome.
- Is H101 in international guidelines like NCCN or ESMO?
- We found it in Chinese expert consensus documents (2022, 2023 and 2025), not in Western treatment guidelines. That reflects its China-only approval and the mostly retrospective nature of the liver-cancer evidence.
- What do grades like '3c' or 'IIb / C' mean?
- They show how confident the experts are. In the CSCO consensus, the H101 + TACE studies are graded 3c, meaning retrospective or observational evidence. In the 2025 perioperative consensus, a IIb evidence level with a grade C recommendation means the approach is reasonable to consider but still exploratory. Higher grades require randomised controlled trials.
Related guides
Oncolytic Virus Therapy (hub)
Overview: what it is, who it may suit, how it's used in China.
Read the guideOncorine (H101) drug profile
Approval, genetic construct, approved indication and milestones.
Read the guideHow oncolytic viruses work
Selective replication, tumour lysis and turning 'cold' tumours 'hot'.
Read the guideH101 + TACE for liver cancer
Evidence, guideline status and treatment protocol for HCC.
Read the guideH101 + PD-1 immunotherapy
Combination data, malignant ascites and immune-microenvironment changes.
Read the guideSafety & side effects
Adverse-event rates from the Phase III trial and combination studies.
Read the guideOncology second opinion
Senior Chinese oncologist reviews your imaging and pathology remotely.
Read the guideSources
References
- Xia ZJ, Chang JH, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23(12):1666–1670.
- Dong J, et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. Med Oncol. 2014;31(8):95.
- Lin XJ, Li QJ, Lao XM, Yang H, Li SP. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC Cancer. 2015;15:707.
- He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chin J Cancer. 2017;36(1):59.
- Wu K, You N, Zheng L. Effects of recombinant human adenovirus type 5 combined with transarterial chemoembolization on postoperative metastasis and recurrence of hepatocellular carcinoma patients. J Gastrointest Oncol. 2021;12(6):2999–3007.
- Zhang Y, Qian L, Chen K, et al. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: characterization of clinical efficacy and antitumor immune response. Mol Ther Oncolytics. 2022;25:31–42.
- Yi L, Ning Z, Xu L, et al. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. ESMO Open. 2024;9(2):102239.
- ASCO 2024 Annual Meeting, J Clin Oncol 2024;42(16_suppl): abstract 2635 (Yuan M et al., TROJAN 021 — H101 + immune checkpoint inhibitors in liver-metastatic gastric cancer, Phase II); abstract 5536 (Zhang Q et al., intratumoral H101 in persistent/recurrent/metastatic gynecological cancer); abstract e16265 (Wang T et al., oncolytic virus + HAIC of mFOLFOX for intrahepatic mass-forming cholangiocarcinoma).
- CSCO Immunotherapy Expert Committee; Shanghai Anti-Cancer Association Tumor Biotherapy Committee. 基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识(2022年版). China Oncology (中国癌症杂志). 2023;33(5). doi:10.19401/j.cnki.1007-3639.2023.05.013
- Interventional Drug Group, Interventional Physicians Branch, Chinese Medical Doctor Association. 原发性肝细胞癌经动脉内用药与联合用药中国专家共识. Chinese Journal of Internal Medicine. 2023;62(7):785–801. doi:10.3760/cma.j.cn112138-20230202-00049
- 肝细胞癌围手术期免疫治疗多学科协作专家共识(2025版). Chinese Journal of Digestive Surgery. 2025;24(6):678–689. doi:10.3760/cma.j.cn115610-20250609-00278
Want the evidence applied
to your case?
Population data only go so far. Send your records and a partner oncologist will explain in writing which of these studies apply to your diagnosis, and whether H101 or a trial is worth considering.
This page is for general education only and is not medical advice. Oncolytic virus therapy is not suitable for every patient or every cancer. In China, Oncorine (H101) is approved only for advanced nasopharyngeal carcinoma in combination with chemotherapy; other uses described here are supported by retrospective studies, small trials, conference abstracts or expert consensus rather than large randomised trials. Treatment decisions are made by the treating oncologist after reviewing your records. We are an independent patient-coordination service and are not affiliated with the manufacturer.